GNSBIO

GNS Bio is a South Korean biotechnology company specializing in the development of advanced biomaterials and drug delivery systems. The company's core technology focuses on injectable hydrogels that provide sustained release of therapeutic agents and serve as physical barriers to prevent post-surgical complications. Their lead candidate, GNS-101, is a long-acting analgesic hydrogel designed for post-operative pain management by delivering bupivacaine over an extended period. Additionally, GNS Bio is expanding its pipeline into treatments for osteoarthritis and anti-adhesion agents, leveraging its proprietary polymer chemistry. The company aims to improve patient outcomes in surgical and orthopedic settings through the convergence of polymer science and pharmacology.